GlassScriptPhysician profile
Mowbray P Hagan
NPI 1235145590
$6,983.87
in general payments reported to CMS, 2019-2025
25 companies · $508 in 2025
The $508 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,184 · 2020: $1,905 · 2021: $1,561 · 2022: $652 · 2023: $596 · 2024: $578 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,682.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,079.87 | 2019-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $1,063.12 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $593.85 | 2019-2025 | Zepbound, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $504.79 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $451.74 | 2019-2025 | Farxiga |
| Abbvie INC. | $375.59 | 2021-2023 | |
| Amarin Pharma, INC. | $359.76 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $344.91 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $198.82 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $178.69 | 2019-2021 | |
| Allergan, INC. | $165.99 | 2019-2020 | |
| Eisai INC. | $153.82 | 2020-2021 | |
| Pfizer INC. | $120.67 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $62.12 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.44 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $48.43 | 2024-2025 | Gemtesa |
| Abbott Laboratories | $45.68 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $36.54 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.61 | 2019-2020 | |
| Dexcom, INC. | $23.85 | 2025 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $21.69 | 2024 | Flector, Licart, Tirosint |
| Exact Sciences Corporation | $20.04 | 2023 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $19.61 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.11 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mowbray Hagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.